title: Marchantin C: a potential anti-invasion agent in glioma cells.
abstract: Cancer cell migration is a leading cause of tumor recurrence and treatment failure. Previously, we reported that marchantin C exhibited promising antitumor activity by inducing microtubule depolymerization and apoptosis. In the present study, we investigated the effect of marchantin C on inhibition of migration in T98G and U87 cells. The scratch-induced migration, Boyden chamber and cell invasion assays were applied to determine that the migrating capacity and invasiveness of these glioma cell lines were inhibited when exposed to marchantin C at a low concentration. There are no obvious signs of apoptosis with this dose. Western blot analyses confirmed that MMP-2, a key role in cancer cell migration, was reduced after incubation with marchantin C in both glioma cell lines. In addition, signaling pathway investigations demonstrated that ERK/MAPK might be involved in MMP-2 downregulation, rather than the AKT/PI3K or JAK/STAT3 pathways. Moreover, marchantin C potently suppressed angiogenesis activity in vivo by CAM assay. This is the first study to demonstrate that marchantin C can inhibit glioma cell migration and invasiveness.
authors.affiliation: Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Gang
authors.initials: G
authors.lastname: Li
authors.forename: Qinglin
authors.initials: Q
authors.lastname: Liu
authors.forename: Qiaowei
authors.initials: Q
authors.lastname: He
authors.forename: Jinhai
authors.initials: J
authors.lastname: Gu
authors.forename: Yanqiu
authors.initials: Y
authors.lastname: Shi
authors.forename: Hongxiang
authors.initials: H
authors.lastname: Lou
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001632:Bibenzyls / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002396:Catechols / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D004988:Ethers, Cyclic / Q000494:pharmacology*; D005910:Glioma / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D010647:Phenyl Ethers / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001632:Bibenzyls; D002396:Catechols; D004988:Ethers, Cyclic; D010647:Phenyl Ethers; D050796:STAT3 Transcription Factor; C459129:marchantin C; D051057:Proto-Oncogene Proteins c-akt; D020778:Matrix Metalloproteinase 2